Haleon bids for Thorne, competing with Unilever’s $4 billion offer
HLN•Haleon has submitted a bid for Thorne, joining Unilever in a sale process valuing the U.S. supplements maker at about $4 billion. Thorne’s 30% compounded annual revenue growth and $650 million in sales highlight high-margin potential for Haleon.
1. Sale Process Underway
Haleon has entered the sale process for Thorne by submitting its own bid, directly challenging Unilever’s proposal valuing the dietary supplements brand at around $4 billion. L Catterton initiated the auction after acquiring Thorne for $680 million in 2023, drawing interest from multiple bidders.
2. Thorne’s Performance Profile
Thorne, operational since 1984, is on track to generate $650 million in annual revenue and has achieved over 30% compounded annual growth under L Catterton’s ownership. The brand’s product range includes magnesium, omega-3 and other wellness supplements with premium pricing and high margins.
3. Strategic Fit for Haleon
Acquiring Thorne would strengthen Haleon’s high-margin consumer healthcare portfolio and deliver additional growth in wellness categories that outperform packaged food. The move aligns with Haleon’s strategy to expand its global supplements footprint and capitalize on resilient consumer demand.
